| 2025 | 2024 | 2023 | ||||
|---|---|---|---|---|---|---|
| Gross margin | -42,5 k € | +41.5% | -72,7 k € | -434.9% | -13,6 k € | |
| EBITDA | -42,5 k € | +41.6% | -72,8 k € | -435.8% | -13,6 k € | |
| Operating profit | -42,5 k € | +41.6% | -72,8 k € | -435.8% | -13,6 k € | |
| Profit/loss | -42,6 k € | +41.5% | -72,9 k € | -436.3% | -13,6 k € | |
| Equity | -126,0 k € | -51.1% | -83,4 k € | -688.3% | -10,6 k € | |
| Total assets | 32,1 k € | +574.9% | 4,8 k € | +110.5% | 2,3 k € | |
| Cash | 22,3 k € | +556.9% | 3,4 k € | +651.9% | 451,0 € | |
| Debts | 154,5 k € | +75.1% | 88,2 k € | +586.6% | 12,8 k € | |
| Staff | 0 | — | — | |||
Source: Belgian Official Gazette
Private limited company · Charleroi · incorporated on 04/08/2023 · 0,0 ETP
Private limited company loss-making in the latest fiscal year. Cash position rising (+556.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
Immunofusion is a Private limited company incorporated in 2023. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi.